We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

64 hedge funds and large institutions have $189M invested in Protagonist Therapeutics in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital invested

Capital invested by funds: $93.2M → $189M (+$96.1M)

7.22% more ownership

Funds ownership: 57.29% → 64.51% (+7.2%)

4% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 23

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

3% less funds holding

Funds holding: 66 → 64 (-2)

Holders
64
Holders Change
-2
Holders Change %
-3.03%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
24
Reduced
23
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
+$6.18M
2
BBA
Baker Bros. Advisors
New York
+$3.57M
3
VMI
VHCP Management III
New York
+$3.41M
4
ACP
Acuta Capital Partners
California
+$2.98M
5
Citadel Advisors
Citadel Advisors
Florida
+$2.9M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$6.43M
2
BI
BVF Inc
California
-$4.56M
3
FCM
Farallon Capital Management
California
-$3.62M
4
American Century Companies
American Century Companies
Missouri
-$762K
5
SIM
Spark Investment Management
New York
-$746K
Name Holding Trade Value Shares
Change 		Change in
Stake
Allianz Asset Management
26
Allianz Asset Management
Germany
$967K +$679K +76,915 New
Invesco
27
Invesco
Georgia
$896K +$629K +71,313 New
Barclays
28
Barclays
United Kingdom
$812K -$35.6K -4,033 -6%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$792K -$2.06K -233 -0.4%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$601K +$288K +32,580 +214%
FI
31
Fosun International
China
$585K -$433K -49,000 -51%
Bank of America
32
Bank of America
North Carolina
$583K +$176K +19,935 +75%
Two Sigma Investments
33
Two Sigma Investments
New York
$577K -$99.7K -11,301 -20%
Squarepoint
34
Squarepoint
New York
$563K +$167K +18,973 +74%
Northern Trust
35
Northern Trust
Illinois
$489K +$37.4K +4,239 +12%
TEE
36
Tibra Equities Europe
United Kingdom
$410K +$288K +32,647 New
Deutsche Bank
37
Deutsche Bank
Germany
$401K +$280K +31,764 +13,810%
ECM
38
ExodusPoint Capital Management
New York
$379K +$141K +15,919 +112%
Citigroup
39
Citigroup
New York
$319K +$224K +25,351 New
SSA
40
Schonfeld Strategic Advisors
New York
$301K +$212K +24,000 New
FSA
41
Franklin Street Advisors
North Carolina
$295K – – –
Jacobs Levy Equity Management
42
Jacobs Levy Equity Management
New Jersey
$273K -$59.1K -6,700 -24%
BCM
43
BlueCrest Capital Management
Jersey
$269K +$62.6K +7,092 +50%
FIM
44
Freedom Investment Management
Connecticut
$259K -$50.6K -5,736 -22%
KWMG
45
King Wealth Management Group
Florida
$245K -$83.9K -9,500 -33%
PPA
46
Parametric Portfolio Associates
Washington
$215K -$13.7K -1,553 -8%
Wells Fargo
47
Wells Fargo
California
$205K -$17.8K -2,016 -11%
AIM
48
Alambic Investment Management
California
$188K – – –
State Street
49
State Street
Massachusetts
$177K -$2.17K -246 -2%
JG
50
Jefferies Group
New York
$177K +$124K +14,100 New
1
2
3 4

PTGX Hedge Fund Activity: Q1 2019 in Review

64 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2019, worth a combined $189M — up 103% from $93.2M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of PTGX and 13 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 24 added.

The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $6.18M. The largest seller was Great Point Partners, exiting entirely with an estimated $6.43M sold.

  • 64 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2019, down from 66 in Q4 2018.
  • Funds reported $189M of Protagonist Therapeutics stock for Q1 2019, up 103% quarter-over-quarter.
  • 13 funds opened new Protagonist Therapeutics positions in Q1 2019 and 14 closed out, a net change of -1 holder.
  • The largest Protagonist Therapeutics buyer in Q1 2019 was Ghost Tree Capital, an estimated $6.18M added.
  • The largest Protagonist Therapeutics seller in Q1 2019 was Great Point Partners, an estimated $6.43M sold.

Based on aggregated 13F filings for Q1 2019.